Precision Oncology Is Changing Lung Cancer Treatment
-
By
-
November 17, 2026
-
5 min
By
November 17, 2026
Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody
June 9, 2026
Misako Nagasaka, MD, PhD shared how precision oncology has fundamentally shifted the landscape through the identification of actionable genomic targets for lung cancer treatment.
June 25, 2026